Exploring the mechanisms of macrolides in cystic fibrosis

Respiratory Medicine

Volumn 100, Issue 4, 2006, Pages 687-697

  Equi, Amanda C ^a,b   Davies, Jane C ^a,b,c   Painter, Hazel ^c,d   Hyde, Stephen ^c,d   Bush, Andrew ^b   Geddes, Duncan M ^a,b,c   Alton, Eric W F W ^a,b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c Cystic Fibrosis Gene Therapy Consortium ^*  (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Azithromycin; CFTR; Ion transport; MDR; Pseudomonas

Indexed keywords

AZITHROMYCIN; MACROLIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ADHERENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; ION TRANSPORT; MALE; NONHUMAN; NOSE MUCOSA; NUCLEOTIDE SEQUENCE; OPEN STUDY; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SODIUM ABSORPTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL ADHESION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; ION TRANSPORT; MALE; NASAL MUCOSA; P-GLYCOPROTEIN; PSEUDOMONAS AERUGINOSA; RNA, MESSENGER; UP-REGULATION; VITAL CAPACITY;

EID: 33344461148     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.07.016     Document Type: Article

References (40)

1. H. Nagai H. Shishido R. Yoneda E. Yamaguchi A. Tamura A. Kurashima Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis Respiration 58 1991 145-149
2. A. Equi I.M. Balfour-Lynn A. Bush M. Rosenthal Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial Lancet 360 2002 978-984
3. J. Wolter S. Seeney S. Bell S. Bowler P. Masel J. McCormack Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial Thorax 57 2002 212-216
4. L. Saiman B.C. Marshall N. Mayer-Hamblett J.L. Burns A.L. Quittner D.A. Cibene et. al. Macrolide Study Group Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial JAMA 1 290 2003 1749-1756
5. J.M. Rommens M.C. Iannuzzi B. Kerem M.L. Drumm G. Melmer M. Dean et. al. Identification of the cystic fibrosis gene: Chromosome walking and jumping Science 245 1989 1059-1065
6. M.J. Welsh A.E. Smith Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis Cell 73 1993 1251-1254
7. H. Matsui B.R. Grubb R. Tarran S.H. Randell J.T. Gatzy C.W. Davis et. al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease Cell 95 1998 1005-1015
8. CF Foundation Patient registry 1994 annual data report 1995 CF Foundation Bethesda, ML
9. S.C. Hyde P. Emsley M.J. Hartshorn M.M. Mimmack U. Gileadi S.R. Pearce et. al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport Nature 346 1990 362-365
10. J.Y. Lallemand V. Stoven J.P. Annereau J. Boucher S. Blanquet J. Barthe et. al. Induction by antitumoral drugs of proteins that functionally complement CFTR: A novel therapy for cystic fibrosis? Lancet 350 1997 711-712
11. T.W. Gant C.K. O'Connor R. Corbitt U. Thorgeirsson S.S. Thorgeirsson In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys Toxicol Appl Pharmacol 133 1995 269-276
12. L. Saiman A. Prince Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells J Clin Invest 92 1993 1875-1880
13. J.C. Davies M. Stern A. Dewar N.J. Caplen F.M. Munkonge T. Pitt et. al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium Am J Respir Cell Mol Biol 16 1997 657-663
14. T. Yamasaki T. Ichimiya K. Hirai K. Hiramatsu M. Nasu Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium J Chemother 9 1997 32-37
15. U. Baumann J.J. Fischer P. Gudowius M. Lingner S. Herrmann B. Tummler et. al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin Infection 29 2001 7-11
16. T. Ichimiya K. Takeoka K. Hiramatsu K. Hirai T. Yamasaki M. Nasu The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro Chemotherapy 42 1996 186-191
17. H. Yasuda Y. Ajiki T. Koga H. Kawada T. Yokota Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin Antimicrob Agents Chemother 37 1993 1749-1755
18. A. Jaffe A. Bush Anti-inflammatory effects of macrolides in lung disease Pediatr Pulmonol 31 2001 464-1773
19. P.G. Middleton D.M. Geddes E.W.F.W. Alton Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium Eur Respir J 7 1994 2050-2056
20. K.J. Livak T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402-408
21. J. Davies A. Dewar A. Bush T. Pitt D. Gruenert D.M. Geddes et. al. Eduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition Eur Respir J 13 1999 565-570
22. E.L. Altschuler Azithromycin, the multidrug-resistant protein and cystic fibrosis Lancet 351 1998 1286
23. A.C. Rose C.A. Goddard W.H. Colledge S.H. Cheng D.R. Gill S.C. Hyde Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways Gene Ther 9 2002 1312-1320
24. U. Pradal A. Delmarco M. Cipolli G. Cazzola Chloride transport may be restored by long-term azithromycin treatment in patients with cystic fibrosis Pediatr Pulmonol S20 2000 280-281
25. L. Saiman Y. Chen P.S. Gabriel C. Knirsch Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis Antimicrob Agents Chemother 46 2002 1105-1107
26. H. Zar L. Saiman L. Quittell A. Prince Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator J Pediatr 126 1995 230-233
27. R.S. Baltimore C.D.C. Christie G.J.W. Smith Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration Am Rev Respir Dis 140 1989 1650-1661
28. E. DiMango H.J. Zar R. Bryan A. Prince Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8 J Clin Invest 96 1995 2204-2210
29. N.J. Caplen E.W. Alton P.G. Middleton J.R. Dorin B.J. Stevenson X. Gao et. al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis Nat Med 1 1995 39-46
30. M. Wilschanski Y. Yahav Y. Yaacov H. Blau L. Bentur J. Rivlin et. al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations N Engl J Med 349 2003 1433-1441
31. A. Di Paolo C. Barbara A. Chella C.A. Angeletti M. Del Tacca Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily Pharmacol Res 46 2002 545-550
32. A. Fietta C. Merlini G. Gialdroni Grassi Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes J Chemother 9 1997 23-31
33. D. Torre M. Broggini V. Botta C. Sampietro R. Busarello C. Garberi In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes J Chemother 3 1991 236-239
34. O. Sakito J. Kadota S. Kohno K. Abe R. Shirai K. Hara Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy Respiration 63 1996 42-48
35. W.L. Hand D.L. Hand N.L. King-Thompson Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes Antimicrob Agents Chemother 34 1990 863-870
36. P.K. Singh A.L. Schaefer M.R. Parsek T.O. Moninger M.J. Welsh E.P. Greenberg Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms Nature 407 2000 762-764
37. H. Yasuda Y. Ajiki T. Koga H. Kawada T. Yokota Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin Antimicrob Agents Chemother 37 1993 1749-1755
38. K. Yanagihara K. Tomono Y. Imamura Y. Kaneko M. Kuroki T. Sawai et. al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model Antimicrob Chemother 49 2002 867-870
39. B.K. Rubin H. Druce O.E. Ramirez R. Palmer Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis Am J Respir Crit Care Med 155 1997 2018-2023
40. U. Baumann M. King E.M. App S. Tai A. Konig J.J. Fischer et. al. Long term azithromycin therapy in cystic fibrosis patients: A study on drug levels and sputum properties Can Respir J 11 2004 151-155